As AstraZeneca Cuts Back In The U.S., It’s Full Steam Ahead In China
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca continues to invest in higher-growth markets like China by acquiring a privately owned injectables generics manufacturer in Guangdong province.
You may also be interested in...
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.
China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.
Samsung, Merck Look To Take On Sanofi’s Lantus With Latest Deal
In the latest win for Samsung Bioepis, the Korean company will help develop and manufacture a late-stage insulin glargine candidate with Merck.